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Abstract A known selective agonist of the A3 adenosine
receptors (AR), MRS1898 [(1′R,2′R,3′S,4′R,5′S)-4-{2-
chloro-6-[(3-iodophenylmethyl)amino]purin-9-yl}-1-
(methylaminocarbonyl)bicyclo[3.1.0]hexane-2,3-diol], was
synthesized in radioactive form and characterized pharma-
cologically. This agonist ligand series, based on nucleoside
analogues containing a rigid, bicyclic ring system in place
of the ribose moiety, was selected for radiolabeling due to
its high A3AR affinity across species, with nanomolar
binding at both rat and human A3ARs. The radioiodination
of MRS1898 on its N
6–3-iodobenzyl substituent was
accomplished in 76% radiochemical yield by iododestan-
nylation of a 3-(trimethylstannyl)benzyl precursor. [
125I]
MRS1898 bound to the rat A3AR with a Kd value of 0.17±
0.04 nM and a Bmax value of 0.66±0.15 pmol/mg protein.
The competition binding profiles for other agonists and
antagonists obtained with this radioligand are similar to those
previously obtained with other radioligands. The advantages
of [
125I]MRS1898 compared with previously used radio-
ligands are primarily its high selectivity and affinity for the
rat A3AR and also its facile synthesis and radiochemical
stability; however, a relatively high level of nonspecific
binding presents a limitation. Thus, we have introduced the
first selective radioligand for the rat A3AR.
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Abbreviations
AR adenosine receptor
CHO Chinese hamster ovary
IB-MECA N
6-(3-iodobenzyl)-5′-N-
methylcarboxamidoadenosine
I-AB-MECA N
6-(4-amino-3-iodobenzyl)-5′-N-
methylcarboxamidoadenosine
MRS1191 1,4-dihydro-2-methyl-6-phenyl-4-
(phenylethynyl)-3,5-pyridinedicarboxylic
acid, 3-ethyl- 5-(phenylmethyl) ester
MRS1220 N-[9-chloro-2-(2-furanyl)[1,2,4]triazolo
[1,5-c]quinazolin-5-yl]benzeneacetamide
MRS1523 5-propyl-2-ethyl-4-propyl-3-(ethylsulfa-
nylcarbonyl)-6-phenylpyridine-
5-carboxylate
MRS1898 MRS1898, (1′R,2′R,3′S,4′R,5′S)-4-{2-
chloro-6-[(3-iodophenylmethyl)amino]
purin-9-yl}-1-(methylaminocarbonyl)
bicyclo[3.1.0]hexane-2,3-diol
NECA 5′-N-ethylcarboxamidoadenosine
Cl-IB-MECA 2-chloro-N
6-(3-iodobenzyl)-5′-
N-methylcarboxamidoadenosine
MRE 3008F20 5-[[(4-methoxyphenyl)amino]carbonyl]
amino-8-propyl-2-(2-furyl)-pyrazolo
[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine
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Introduction
Adenosine regulates many physiological functions through
specific cell membrane receptors. The A3 adenosine
receptor (A3AR) plays an important role in brain ischemia,
immunosuppression, and bronchospasm in several animal
models [1]. A3AR agonists, such as Cl-IB-MECA (2,
Chart 1), are currently in clinical trials for various me-
tastatic and inflammatory conditions [2–5]. The A3AR is
elevated in tumors, and its expression level correlates to
tumor responsiveness to therapy, such as the A3AR agonist
N
6-(3-iodobenzyl)-5′-N-methylcarboxamidoadenosine (IB-
MECA 1) [6, 7].
A number of radioligands have been used for the study
of the A3AR [8–12]. Radioligands for the A3AR may be
promising diagnostic markers for cancer and possibly other
diseases, whereas characterization and quantification of the
A3AR in vivo in patients may also be a useful tool in both
research and therapeutic studies [13]. The nucleoside N
6-(4-
amino-3-iodobenzyl)-5′-N-methylcarboxamidoadenosine
([
125I]I-AB-MECA 3) (Kd ∼ 1 nM at human (h) and rat (r)
A3AR) was introduced in 1994 as a radioligand for A3AR
and is the most commonly used radioligand for in vitro
studies of that subtype [8]. Several other agonist radio-
ligands have been used in previous studies. All of the
A3AR radioligands so far in use show major deficiencies.
For example, the antagonist heterocyclic radioligands, [
3H]
MRE 3008F20 4 and [
3H]PSB-11 5, have been used for the
study of the hA3AR; however, they do not bind effectively
to the rA3AR or mouse A3AR [9, 10]. A3AR agonists are
often more consistent than nonnucleoside antagonists in
their high affinity at that subtype, independent of species.
Nevertheless, most of the agonist radioligands for charac-
terizing the A3AR are not truly A3AR selective. Although
the agonist N
6-(4-amino-3-iodophenylethyl)-adenosine
([
125I]I-APNEA) showed reasonable affinity for the rA3AR
(Kd=15 nM), it is even more potent for the rA1AR (Kd=
1.32 nM) [8,21]; [
125I]I-AB-MECA 3 has a similar affinity
for rA1 and rA3ARs (A3=1.48 nM; A1=3.42 nM). 5′-N-
ethylcarboxamidoadenosine ([
3H]NECA), showed a rea-
sonable binding affinity at the hA3AR (Kd=6 nM) but is
nonselective and weak at the rA3AR [11]. Recently, a new
A3AR agonist radioligand, [
3H]HEMADO 6, which con-
tains an N
6-methyl group, showed high affinity (Kd=
1.1 nM at the hA3AR), selectivity, and low nonspecific
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Chart 1 Structures of nucleoside and nonnucleoside, high-affinity ligands for the A3 adenosine receptor. Compounds 3–6 were previously
prepared in radioactive form for use in receptor labeling and characterization
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which is consistent with previous findings that N
6-methyl-
substituted adenosine derivatives are potent at the hA3AR
but not rA3AR [14, 15]. For example, the parent nucleoside
N
6-methyladenosine has Ki values of 6390 nM at the
rA3AR and 9.3 nM at the hA3AR.
Thus, the challenge remains to develop a subtype-
selective radioligand for the A3AR in rat and other non-
primate species. A new nucleoside derivative, (1′R,2′R,3′
S,4′R,5′S)-4-{2-chloro-6-[(3-iodophenylmethyl)amino]
purin-9-yl}-1-(methylaminocarbonyl)bicyclo[3.1.0]hexane-
2,3-diol) (MRS1898 7), containing the (N)-methanocarba
(bicyclo[3.1.0]hexane) ring system as a ribose substitute,
displays high potency and selectivity for the hA3AR
compared with other A3AR agonists, such as IB-MECA 1
[16–18]. This bicyclic ring system maintains a conformation
that is preferred at the A3AR and thus tends to increase
selectivity for the hA3AR. MRS1898 7 has previously been
shown to bind with high affinity at the rA3AR. Its affinity
profile at three AR subtypes is as follows: rA1=83.9 ±
10.3 nM, hA1=136±22nM;rA2A=1660 ± 260 nM, hA2A=
784 ± 97 nM; rA3=1.1 ± 0.1 nM, hA3=1.51 ± 0.23 nM. In
this study, we synthesized a radioiodinated form of this
adenosine derivative for preliminary in vitro studies and
characterized its binding properties at the rA3AR.
Materials and methods
General All chemical synthetic reagents and pharmacologi-
cal agents were purchased from Sigma-Aldrich Chemical
Company, except where noted. Sodium [
125I]iodide
(17.4 Ci/mg) in sodium hydroxide (NaOH) (1.0x10
–5 M)
was supplied by Perkin–Elmer Life and Analytical Science.
Iodogen iodination reagent was purchased from Pierce
Biotechnology. High-performance liquid chromatography
(HPLC) was performed using an Agilent 1200 Series LC-
MS system or a Beckman Gold HPLC system equipped
with a Model 126 programmable solvent module, a Model
168 variable wavelength detector, a β–Ram Model 4
radioisotope detector, and Beckman System Gold remote
interface module SS420X, using 32 Karat® software. These
analyses were performed on Agilent Eclipse XDB-C18
(3.5 μm, 3.0 x 75 mm) and XDB-C18 (5 μm, 4.6 x
250 mm) columns.
Preparation of [
125I]MRS1898 [(1′R,2′R,3′Σ,4′R,5′Σ)-4-
{2-chloro-6-[(3-iodophenylmethyl)amino]purin-9-yl}-1-
(methylaminocarbonyl)bicyclo[3.1.0]hexane-2,3-diol] (10)
MRS1898 (0.018 g, 0.033 mmol), PdCl2(PPh3)2 (5 mg),
and hexamethyltin (0.032 g, 0.1 mmol) were mixed
together in anhydrous dioxane (3 ml), and the resulting
reaction mixture was stirred at 70 ˚C for 2 h. The mixture
was concentrated under reduced pressure. The product was
purified by preparative thin layer chromatography by using
chloroform (CHCl3): MeOH as the eluant to afford the
stannyl derivative 1 (0.008 g, 45%) as an oil. High-
resolution mass spectrometry (HRMS) (M+ 1)
+ : calculated
593.1090, found 593.1099. HPLC: Rt=21.95 min. HPLC
system: 5 mM TBAP/CH3CN from 80/20 to 60/40 in
25 min, then isocratic for 2 min; flow rate of 1 ml/min.
Regeneration of MRS1898 The trimethylstannyl intermedi-
ate 10 (0.1 mg) was reconverted to MRS1898 upon dis-
solving in MeOH (0.1 ml) followed by treatment with I2
(0.1 M in MeOH, 0.1 ml) for 10 min at room temperature
(Scheme 1). The structure was confirmed by HPLC and
HRMS. HRMS (M+ 1)
+ : calculated 555.0408, found
555.0408. HPLC: Rt=15.91 min (same system as above).
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Scheme 1 Synthesis of a
stannyl precursor 10 and the
iodination (reverse) reaction
used in nonradioactive genera-
tion of [(1′R,2′R,3′Σ,4′R,
5′Σ)-4-{2-chloro-6-[(3-iodophe-
nylmethyl)amino]purin-9-yl}-1-
(methylaminocarbonyl)bicyclo
[3.1.0]hexane-2,3-diol]
(MRS1898)
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subsequent radioiodination conditions, the trimethylstannyl
precursor 10 (0.2 mg, 0.34 μmol) was dissolved in 50 ul of
methanol in an Eppendorf vial, and to this solution was
added an iodine–methanol solution (100 ul of 8 mg/ml).
The vial contents were shaken for 30 min and the crude
product analyzed on an Agilent 1200 Series Liquid-
Chromatography Mass Spectrometry (LC-MS). MRS1898
eluted at 7.6 min with a molecular weight of 555.1 that
showed [M + H]
+.
Radiolabeling of MRS1898: method 1 The radioiodination
of MRS1898 was performed using tert-butyl hydroperoxide
(TBHP) as an oxidant (Scheme 2)[ 19]. Next, 15 ul of
TBHP (10% solution in chloroform) was added into a v-
vial. To this solution were added an acetic acid solution
(4 ul, 3% in chloroform) and a sodium [
125I]iodide solution
(4 ul, 14.8 MBq, 3.7 GBq/ml), followed by the trimethyl-
stannyl precursor 10 (50 ul, 0.2 mg in chloroform). The
reaction mixture was mixed under vortex for 30 min at
room temperature. The final labeled product was separated
using a Beckman System Gold HPLC equipped with an
Agilent Eclipse XDB-C18 column (5.0 μm, 4.6×250 mm)
under the following conditions: solvent A was 0.1%
trifluoroacetic acid (TFA) in water; solvent B was 0.1%
TFA in acetonitrile. A linear gradient of solvent B from
20% to 50% over 25 min was used at a flow rate of 1 ml/min;
[
125I]MRS1898 eluted at 23 min. The fraction containing
[
125I]MRS1898 was concentrated and loaded onto an Agilent
Eclipse XDB-C18 column (3.5 μm, 3.0×75 mm). The
mobile phase was the same as above , and a linear gradient
of solvent B from 20% to 45% over 12 min was used at a
flow rate of 1 ml/min; [
125I]MRS1898 eluted at 9.0 min. The
radiochemical purity was >98%, the specific activity was
3.94 Ci/mg, and the radiochemical yields were 75.6%.
Radiolabeling of MRS1898: method 2 The second radio-
iodination of the trimethylstannyl MRS1898 10 with Na
[
125I] iodide was accomplished using iodogen as an oxidant
(Scheme 2). Iodogen solution (60 ul, 0.33 mg/ml in
chloroform) and sodium [
125I]iodide solution (3 ul,
11.1 MBq, 3.7 GBq/ml) were transferred into a v-vial. To
this solution was added the trimethylstannyl precursor 10
(50 ul, 0.2 mg in chloroform). The reaction mixture was
mixed under vortex for 30 min at room temperature, and
the [
125I]MRS1898 was purified using the same conditions
as used in method 1. The radiochemical purity was >98%,
the specific activity was 3.94 Ci/mg, and the radiochemical
yield was 54.5%. The [
125I]MRS1898 was stored in
solution (ethanol: water=9:1, v/v) containing 1% ascorbic
acid for inhibition of radiolytic processes.
Pharmacology
The binding experiments were done as previously described
[8, 14] on Chinese hamster ovary (CHO) cell membranes
expressing the recombinant rA3AR and on membranes
from rat-brain cortex, mainly expressing the A1AR; and rat
striatum, expressing the A2AAR endogenously. In brief, the
saturation, displacement and kinetic experiments were
performed using membrane preparations from CHO cells
expressing rA3AR in a total assay volume of 100 μl, in-
cluding 25 μl of radioligand, 50 μl membranes, and 25 μl
of test compounds or other ingredients. Nonspecific binding
was determined in the presence of 10 μM IB-MECA. The
mixtures were incubated at 25°C for 60 min, followed by
filtration with a 24-well Brandell MT-24 harvester. Radio-
activity was determined in a Beckman 5500B γ-counter.
For the dissociation experiment, the mixture was first
incubated for 60 min, 10 μM IB-MECA was added, and
reaction was terminated at various time points, as indicated.
Binding parameters were calculated using Prism 4.0
software (GraphPAD, San Diego, CA, USA). IC50 values
obtained from competition curves were converted to Ki
values using the Cheng-Prusoff equation [20]. Data are
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calculated using ChemDraw Ultra (Version 11.0).
Results
Chemistry
It was hoped that a new radioligand would permit better
analysis of tissue distribution of the A3AR. As MRS1898
already contains an iodine atom that is associated with high
receptor affinity, that position was selected for convenient
radiolabeling. A common method for rapidly introducing
radioactive iodine on an aromatic ring is to use a stannyl
precursor. The feasibility of this route was demonstrated
through a “cold” iodination reaction (Scheme 1). The
trimethylstannyl precursor 10 was generated in one step
from MRS1898 using a palladium reagent and hexame-
thyltin. Protection of the hydroxyl groups or the exocyclic
amine of this adenosine analogue was not necessary.
Compound 10 was stable upon storage at −8˚C for several
months. This intermediate 10 rapidly reverted to MRS1898
upon treatment with iodine. The radioiodination of
MRS1898 was accomplished through a similar iododestan-
nylation of 10 using sources of
125I and by two different
radioiodination methods (Scheme 2). The tertiary-butyl
hydroperoxide (TBHP) method [19] provided a superior
yield in comparison with iodogen. The stability of [
125I]
MRS1898 solution (ethanol:water=9:1, v/v) containing 1%
ascorbic acid over 1 month when stored at −20°C was
reliable, as reported in Table 1.
Pharmacology
The new radioligand was examined in standard radio-
receptor binding experiments. The rA3AR was expressed
heterologously in CHO cells [21], from which membranes
were prepared for binding experiments. Initially, the
nonspecific binding of [
125I]MRS1898 to CHO cell
membranes expressing the rA3AR was extremely high,
almost inseparable from its total binding. After soaking the
glass fiber filters with polyethyleneimine (0.1%), the ratio
of specific to nonspecific binding (at a concentration of
0.1 nM radioligand) was improved (3–4:1) and acceptable
Table 1 The radiochemical purities of a (1′R,2′R,3′S,4′R,5′S)-4-{2-
chloro-6-[(3-iodophenylmethyl)amino]purin-9-yl}-1-(methylamino-
carbonyl)bicyclo[3.1.0]hexane-2,3-diol ([
125I]MRS1898) solution at
various time points
a
Time (days) 2 8 11 20 25 27
Radiochemical purity 98% 98.5% 98.5% 100% 100% 100%
aDetermined by high-performance liquid chromatography (HPLC)
with radioactivity detection. [
125I]MRS1898 was present at a con-
centration of 6.9 nM in solution (ethanol:water=9:1, v/v) containing
1% ascorbic acid and stored at −20°C.
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Fig. 1 Saturation of binding of (1′R,2′R,3′S,4′R,5′S)-4-{2-chloro-6-
[(3-iodophenylmethyl)amino]purin-9-yl}-1-(methylaminocarbonyl)
bicyclo[3.1.0]hexane-2,3-diol ([
125I]MRS1898) at the rat A3
adenosiner receptor (AR). Experiments were performed using mem-
brane preparations (20 μg protein) from Chinese hamster ovary
(CHO) cells expressing rat A3AR in a total assay volume of 100 μl,
including 25 μl of radioligand, 50 μl membranes, and 25 μl buffer
(total binding) or 25 μlo f1 0μM N
6-(3-iodobenzyl)-5′-N-methyl-
carboxamidoadenosine (IB-MECA) (nonspecific binding). The mix-
tures were incubated at 25°C for 60 min, followed by filtration with a
24-well harvester
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Fig. 2 Competition for binding of (1′R,2′R,3′S,4′R,5′S)-4-{2-chloro-6-
[(3-iodophenylmethyl)amino]purin-9-yl}-1-(methylaminocarbonyl)bicy-
clo[3.1.0]hexane-2,3-diol ([
125I]MRS1898) (0.1 nM) at the rat A3
adenosine receptor (AR) by A3AR agonists and antagonists. The y-
axis shows radioactivity counts corresponding to total binding. The Ki
values (nM ± standard error of the mean) were: 1,4-dihydro-2-methyl-6-
phenyl-4-(phenylethynyl)-3,5-pyridinedicarboxylic acid, 3-ethyl- 5-
(phenylmethyl) ester (MRS1191) (1,850±386), N-[9-chloro-2-(2-furanyl)
[1,2,4]triazolo[1,5-c]quinazolin-5-yl]benzeneacetamide (MRS1220)
(>10,000), 5-propyl-2-ethyl-4-propyl-3-(ethylsulfanylcarbonyl)-6-phenyl-
pyridine-5-carboxylate (MRS1523) (518±236), MRS1898 (7.8±2.5), N
6-
(3-iodobenzyl)-5′-N-methylcarboxamidoadenosine (IB-MECA) (12.9±
3.7) and 5′-N-ethylcarboxamidoadenosine (NECA) (872±251)
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the radioligand concentration was raised.
The specific binding of [
125I]MRS1898 to the rA3AR in
CHO cell membranes was saturable (Fig. 1), and Scatchard
analysis indicated a Kd value of 0.17±0.04 nM and a Bmax
value of 0.66±0.15 pmol/mg protein.
The ability of various known AR agonists and antago-
nists to compete for [
125I]MRS1898 binding to the rA3AR
was tested. Figure 2 shows that the rank order of potencies
for agonists was MRS1898 ≥ IB-MECA > NECA, and for
antagonists 5-propyl-2-ethyl-4-propyl-3-(ethylsulfanyl-
carbonyl)-6-phenylpyridine-5-carboxylate (MRS1523) >
1,4-dihydro-2-methyl-6-phenyl-4-(phenylethynyl)-3,5-pyri-
dinedicarboxylic acid, 3-ethyl- 5-(phenylmethyl) ester
(MRS1191) > N-[9-chloro-2-(2-furanyl)[1,2,4]triazolo[1,5-
c]quinazolin-5-yl]benzeneacetamide (MRS1220), which is
similar to those obtained with other radioligands in pre-
vious reports.
In the association kinetic experiment (Fig. 3A), [
125I]
MRS1898 binding reached a maximum in 30 min, with a t1/2
of 7.4±0.9 min. After a 60 min incubation, the dissociation
was initiated with the addition of 10 μM IB-MECA at
various time points, as indicated in Fig. 3b.
The binding of [
125I]MRS1898 was further tested using
membranes prepared from rat-brain cortex (mainly A1AR)
and striatum (expressing both A1AR and A2AAR). It was
found that no specific binding to either the rA1AR or
rA2AAR could be demonstrated (Fig. 4) at both low
(0.1 nM) and high (1.0 nM) concentrations of [
125I]
MRS1898 using a membrane concentration as high as
200 μg/mg protein.
Discussion
In this study, we synthesized and pharmacologically
characterized the new radioligand [
125I]MRS1898 for the
rA3AR. The agonist ligand series of which MRS1898 is
representative, based on nucleoside analogues containing a
rigid, bicyclic ring system in place of the ribose moiety,
was selected for radiolabeling due to its high A3AR affinity
across species. The radioiodination of MRS1898 on its
N
6–3-iodobenzyl substituent was accomplished in 76%
radiochemical yield by iododestannylation of a 3-(trime-
thylstannyl)benzyl precursor 10. This precursor was both
synthesized and iodinated without protecting groups present
at other sensitive positions of the nucleoside.
As a receptor radioligand, [
125I]MRS1898 may be useful
for compound screening, testing of ligand binding affinity,
and for studying association and dissociation kinetics at the
rA3AR. Although [
125I]MRS1898 could be potentially
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Fig. 3 Kinetics of association (a) and dissociation (b)o f( 1 ′R,2′R,3′
S,4′R,5′S)-4-{2-chloro-6-[(3-iodophenylmethyl)amino]purin-9-yl}-1-
(methylaminocarbonyl)bicyclo[3.1.0]hexane-2,3-diol ([
125I]
MRS1898) (0.1 nM) at the rat A3 adenosine receptor
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Fig. 4 Binding of (1′R,2′R,3′S,4′R,5′S)-4-{2-chloro-6-[(3-iodophe-
nylmethyl)amino]purin-9-yl}-1-(methylaminocarbonyl)bicyclo[3.1.0]
hexane-2,3-diol ([
125I]MRS1898) in membranes from rat-brain cortex
[mainly A1 adenosine receptor (AR)] and striatum (expressing both
A1AR and A2AAR). Two concentrations of [
125I]MRS1898 (0.1 and
1 . 0n M )w e r eu s e d .T h em e m b r a n ec o n c e n t r a t i o nu s e di nt h e
experiment was 200 μg/mg protein). The y-axis shows radioactivity
counts. The first bar (TB, total binding) in each pair of bars
corresponds to total radioligand binding, and the second bar (NSB,
nonspecific binding) is in the presence of 10 μM N
6-cyclopentylade-
nosine for A1AR and 10 μM 2-[p-(2-carboxyethyl)phenyl-ethyl-
amino]-5′-N-ethylcarboxamidoadenosine for A2AA R .T h u s ,n o
specific binding of [
125I]MRS1898 to the A1AR and A2AAR in rat
brain was detected
36 Purinergic Signalling (2009) 5:31–37useful for the study of the rA3AR, there are also some
potential problems with this radioligand, particularly its
high nonspecific binding under the conditions used in this
study. The Kd value of the radioligand was somewhat lower
than that estimated from the affinity of the nonradiolabeled
MRS1898, which may be affected by its hydrophobic
nature. The cLogP for MRS1898 was 2.43, which was
considerably higher than the cLogP (1.20) for the corre-
sponding 9-riboside, Cl-IB-MECA 2. The frequently used
radioligand I-AB-MECA 3 had a cLogP of −0.47. Thus,
further efforts are needed toward the design of a similar
radioligand with subnanomolar affinity and subtype selec-
tivity, but with lower nonspecific binding, for applications
such as autoradiography. Nevertheless, our study demon-
strated that [
125I]MRS1898 should be useful under certain
conditions for the study of the rA3AR. Its A3AR selectivity
is clearly superior to the widely used [
125I]I-AB-MECA.
In summary, a novel selective A3AR radioligand, [
125I]
MRS1898, was synthesized and pharmacologically charac-
terized in binding to cell membrane receptors. The advan-
tages of this radioligand compared with other previously
used radioligands are its facile synthesis and radiochemical
stability and its high selectivity and high affinity for the
rA3AR, which should be applicable for the study of A3AR in
native tissues with mixed AR subtypes. The binding of [
125I]
MRS1898 to the A3AR in other species and the feasibility of
its use in quantification of the A3AR from various tissues
may now be studied.
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